1-6 of 6
Karim A. Benhadji
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer

Ryan J. Sullivan, Antoine Hollebecque, Keith T. Flaherty, Geoffrey I. Shapiro, Jordi Rodon Ahnert, Michael J. Millward, Wei Zhang, Ling Gao, Amanda Sykes, Melinda D. Willard, Danni Yu, Andrew E. Schade, KrisAnne Crowe, Daniel L. Flynn, Michael D. Kaufman, James R. Henry, Sheng-Bin Peng, Karim A. Benhadji, Ilaria Conti, Michael S. Gordon, Ramon V. Tiu, David S. Hong
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2020) 19 (2): 460–467.
https://doi.org/10.1158/1535-7163.MCT-19-0681
Published: 06 February 2020
View article titled, A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer
Open the PDF for A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract C261: Pharmacokinetics (PK) and pharmacodynamics (PD) of the oral transforming growth factor-beta (TGF-β) receptor I kinase inhibitor LY2157299 monohydrate (LY) in hepatocellular carcinoma (HCC) compared to glioma patients.

Eric Raymond, Sandrine Faivre, Armondo Santoro, Robin K. Kelley, Robin K. Kelley, Philippe Merle, Ed Gane, Jean-Yves Douillard, Dirk Waldschmidt, Mary Mulcahy, Charlotte Costentin, Beatriz Minguez, Luca Di Lena, Ivelina Gueorguieva, Colin Miles, Ann Cleverly, Michael M. Lahn, Sophie Ameryckx, Karim A. Benhadji, Gianluigi Giannelli
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C261.
https://doi.org/10.1158/1535-7163.TARG-13-C261
Published: 01 November 2013
View article titled, Abstract C261: Pharmacokinetics (PK) and pharmacodynamics (PD) of the oral transforming growth factor-beta (TGF-β) receptor I kinase inhibitor LY2157299 monohydrate (LY) in hepatocellular carcinoma (HCC) compared to glioma patients.
Journal Articles

Abstract A228: TGF-beta signaling inhibition using LY2157299 affects proliferation or invasion in hepatocarcinoma cells and patient samples.

Marie Serova, Annemilaï Tijeras-Raballand, Celia Dos Santos, Karim A. Benhadji, Valerie Paradis, Eric Raymond, Sandrine Faivre, Armand de Gramont
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A228.
https://doi.org/10.1158/1535-7163.TARG-13-A228
Published: 01 November 2013
View article titled, Abstract A228: TGF-beta signaling inhibition using LY2157299 affects proliferation or invasion in hepatocarcinoma cells and patient samples.
Journal Articles

Abstract B175: TGF-β-RI kinase inhibitors LY2157299 and LY364947 decrease motility and invasion in hepatocarcinoma (HCC) cells developing resistance to VEGFR/PDGFR kinase inhibitors.

Maria Serova, Maria Eugenia Riveiro, Armand de Gramont, Annemilai Tijeras-Raballand, Ivan Bieche, Matthieu Martinet, Mohamed Bouattour, Karim A. Benhadji, Eric Raymond, Sandrine Faivre
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): B175.
https://doi.org/10.1158/1535-7163.TARG-11-B175
Published: 12 November 2011
View article titled, Abstract B175: TGF-β-RI kinase inhibitors LY2157299 and LY364947 decrease motility and invasion in hepatocarcinoma (HCC) cells developing resistance to VEGFR/PDGFR kinase inhibitors.
Journal Articles

Epithelial-to-Mesenchymal Transition and Oncogenic Ras Expression in Resistance to the Protein Kinase Cβ Inhibitor Enzastaurin in Colon Cancer Cells

Maria Serova, Lucile Astorgues-Xerri, Ivan Bieche, Sebastien Albert, Michel Vidaud, Karim A. Benhadji, Shahin Emami, Dominique Vidaud, Pascal Hammel, Nathalie Theou-Anton, Christian Gespach, Sandrine Faivre, Eric Raymond
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (5): 1308–1317.
https://doi.org/10.1158/1535-7163.MCT-10-0167
Published: 09 May 2010
View article titled, Epithelial-to-Mesenchymal Transition and Oncogenic Ras Expression in Resistance to the Protein Kinase Cβ Inhibitor Enzastaurin in Colon Cancer Cells
Open the PDF for Epithelial-to-Mesenchymal Transition and Oncogenic Ras Expression in Resistance to the Protein Kinase Cβ Inhibitor Enzastaurin in Colon Cancer Cells in another window
Journal Articles

Effects of protein kinase C modulation by PEP005, a novel ingenol angelate, on mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling in cancer cells

Maria Serova, Aïda Ghoul, Karim A. Benhadji, Sandrine Faivre, Christophe Le Tourneau, Esteban Cvitkovic, Francois Lokiec, Janet Lord, Steven M. Ogbourne, Fabien Calvo, Eric Raymond
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2008) 7 (4): 915–922.
https://doi.org/10.1158/1535-7163.MCT-07-2060
Published: 15 April 2008
View article titled, Effects of protein kinase C modulation by PEP005, a novel ingenol angelate, on mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling in cancer cells
Open the PDF for Effects of protein kinase C modulation by PEP005, a novel ingenol angelate, on mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling in cancer cells in another window